Late Breaking News

click to listen (212 KB)

As PXE Awareness was going to press, the NAPE Office received from a PXE patient news of a new drug, VEGF Trap, developed by Regeneron Pharmaceuticals, which inhibits the VEGF stimulus of blood vessel growth under the retina.

Regeneron's preliminary single-dose treatment of 21 patients was quite positive. Regeneron reports that 95% of those receiving the single dose treatment experienced stabilization and/or improved visual acuity. A Phase 2 trial will begin soon with 150 patients.

The NAPE Office will follow this study very closely and you can do so, too, with an initial look at Regeneron's website at www.regeneron.com.